MedTrace Logo

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-03

No results posted yet for this study

Summary

In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT).

Conditions

Interventions

DRUG

[18F]FLT

\[18F\]FLT PET/CT scan, imaging tracer

DEVICE

PET/CT

\[18F\]FLT PET/CT scan

DRUG

ribociclib

therapeutic

DRUG

paclitaxel

therapeutic

Sponsors & Collaborators

Principal Investigators

  • David Mankoff, MD, PhD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608216 on ClinicalTrials.gov